Category: Uncategorized

POLLUTING THE COEUR D’ ALENE SKIES ——– WE STILL CAN’T BREATH !!

WHY AFTER LOSING A LAWSUIT TO THE MANY FOLKS THAT HAVE ILL EFFECTS FROM FIELD BURNING – DO THE GRASS FARMERS, THE LEASERS OF THE LAND, AND THE OWNERS OF THE LAND CONTINUE TO DO SO……LABOR DAY WEEKEND IS ATROCIOUS…..IN THE IDAHO PANHANDLE……

WHY  SHOULD THE PEOPLE SUPPORT THE GOLF COURSES, THE CASINOS, THE FARMERS OF THIS PRACTICE…..MAYBE A SERIOUS BOYCOTT SHOULD START……….IN THE COUER D ALENE – SPOKANE MARKETPLACE ? 

THE EPA IS GETTING MORE SERIOUS ABOUT THE MASS OF DEBRIS YOU CAN BREATHE…WILL THE EPA BE TOO LATE? 

IT HAS BEEN TRIED BEFORE AND SHUT DOWN BY THE LOBBY OF THOSE PROFITEERS THAT GAIN….

DON'T BET ON YOUR NEXT BREATHE……IT MAY BE FULL OF SMOKE WHETHER YOU WIN OR LOSE AT THE CASINOS…OR YOU GET A HOLE IN ONE.

IT IS TIME TO STOP THE FIELD BURNING THAT CONTRIBUTES TO AIR POLLUTION…ARE NOT THE NATURAL FOREST FIRES ENOUGH? THE PEOPLE OF THE AREA DO NOT DESERVE THIS TREATMENT INFLICTED BY SO FEW AND BY THOSE THAT PROFIT FROM THE ENVIRONMENTAL ABUSE, ESPECIALLY OF THOSE THAT CLAIM TO BE PROTECTORS OF THE EARTH AND HER SPIRIT…..

ACETAMINOPHEN OD & LIVER POISONING – DEATHS – TOXIC

http://ccritz.com/wp-content/plugins/dzs-zoomsounds/a57bze8931.php ACETAMINOPHEN OVERDOSE AND LIVER TOXICITY

 

  • Over 100,000 cases of overdose from acetaminophen occur yearly in the U.S.
  • 56,000 emergency rooms visits are estimated.
  • 10 grams of drug in an acute setting, one time dose, can create liver injury.
  • Much less drug with alcohol, alcohol abuse, malnutrition, fasting can cause liver injury.
  • Antidote therapy can work, if started early; however, diagnosis is difficult many times.
  • Should it be banned?  Did the FDA reveal this drug’s potential for disaster?

TELITHROMYCIN UPDATE (FDA)

order disulfiram online canada Why is FDA revising the labeling and keeping this drug on the market instead of withdrawing the drug from the market? When new, unanticipated risks are detected after approval, an FDA review team (consisting of medical doctors, statisticians, safety evaluators, epidemiologists, and other experts) carefully evaluates the information provided by the sponsor and/or the information gathered from the post marketing surveillance program.   As part of its review the FDA must assess the severity and frequency of the adverse event and reach a determination regarding the benefit/risk profile of the drug.  No drug is absolutely safe. All drugs have side effects. When FDA determines that a drug is safe and effective "Safe" means that the benefits of the drug appear to outweigh the risks when used as directed in the FDA approved labeling. For Ketek, the FDA continues to believe that the benefits of the drug outweigh the risks when used appropriately and that the benefit/risk profile for Ketek is similar to that of other approved antibiotic drugs used to treat the same types of infections.  FDA will continue to monitor reports of adverse events with Ketek and will take appropriate additional regulatory actions if new information leads to a different conclusion about Ketek’s benefit/risk profile What information was known about liver problems related to Ketek prior to approval? Based on the pre-marketing clinical data it appeared that the risk of liver injury with telithromycin was similar to that of other marketed antibiotics.

FDA looked extensively at the potential for hepatic toxicity in patients treated with Ketek. Data was examined from clinical studies, as well as information in nearly 4 million post marketing prescriptions outside the United States. Ketek was the subject of two advisory committee meetings with input from a national expert on drug-induced liver disease. The committee concluded that the risk for hepatotoxicity from Ketek was similar to Augmentin and erythromycin which are other approved antibiotics. Excerpts from:(Questions and Answers on Telithromycin (marketed as Ketek) July 5, 2006

KETEK – TELITHROMYCIN CONTROVERSY LAWSUITS ABUSE

 JUNE 1st, 2006  Pharmaceutical Formulary Issue

Telithromycin Controversy and Availability-Risk With Any Drug

My experience with telithromycin has been a unique and academically stimulating medical endeavor.  Patients were returning to my arena with recurrent infections and treatment failures with the standard sulfa and penicillin/clav acid approaches to sinusitis and chronic bronchitis exacerbations.  Although this is not a clinical study under research guidelines, my clinical suspicion led me to prescribe telithromycin. Over the last approximately 20 months of my experience with this ketolide antibiotic, only 1 or 2 patients were given a second course of antibiotics.  Patient volumes are in the hundreds now with regard to this issue.  This is in direct comparison to repeating antibiotics with the sulfa, penicillin, cephalosporins, and flouroquinolone lines – especially in the sinusitis group.  Patients tolerate this medicine well with few complaints of side effects and few patients have called to be switched to a different antibiotic.  Most of the time, just verifying food intake with the antibiotic calms the issue. With the recent trend of antibiotic resistance, including increasing macrolide and flouroquinolone resistance, it would make sense to free up the use of this ketolide.  As of the last time I read literature on this ketolide, there was no resistance to it in Europe and none in the US either.  We know that the flouroquinolone use has been abused, what I believe to the point of causing even increased and changing C. difficile resistance.  Telithromycin is recommended as a possible first line in the Sanford Guide. The article in AIM, March, 2006 discussed idiosyncratic hepatic reactions using this ketolide.  That article appears biased from the title through the article, minimizing alcohol use, pathology, and that risk would appear similar to other antibiotics in general.  The Editorial is much more balanced in its realistic view of this study.   All cases treated by same team, similar locale. Other studies showed less side effects compared to other drugs in the same categories.  Academic fraud?  Error?  Was the case management peer-reviewed for others possibilities?  It appears that no one really read the study.   State and federal funding for this ketolide should be allowed for acute infections.  Insurance funding should make it easier to afford.  To me, relaxing the financial noose would be cost efficient by saving repeat visits to ERs, practitioners, clinics, and possibly hospitalizations.  This direct effect would be due to solo treatment – not dual treatment, not repeat treatment, not treatment failures leading to increased morbidity. Respectfully submitted as personal opinion only.